Citi Analysts Say GSK Earnings Call Left Questions on HIV Pipeline, 2027 Outlook

Citi analysts said GSK’s third-quarter earnings call left questions unanswered about its HIV medicines pipeline and 2027 outlook. GSK said it is analyzing data from a long-acting HIV-prevention drug before sharing it with regulators.